Articles tagged with Liver Cancer
Researchers have developed a method to identify splicing-based biomarkers for hepatocellular carcinoma (HCC), the most common form of liver cancer. These biomarkers may help predict disease progression and are associated with poor patient survival.
Researchers discovered that polyploid liver cells can protect the liver against cancer by carrying extra copies of tumor suppressor genes. This finding challenges the notion that polyploidy is a pro-cancer state and suggests it could be an adaptive response within normal liver cells.
Combining a blood test for high alpha fetoprotein (AFP) levels with ultrasound imaging improves liver cancer detection by 40 percent, according to researchers at UT Southwestern Medical Center. Early detection is crucial for improving survival rates in patients with liver cancer, which is on the rise in the US.
Researchers have developed a new method to grow patient-derived xenografts (PDX) liver cancer cells in culture, which maintains their proper shape and function and grows as organoids. The success of the engineered organoids has the potential to revolutionize the screening and development of liver cancer drugs.
Researchers discover a two-step process to kill liver cancer cells by silencing an enzyme and adding metformin, potentially accelerating new treatments for this deadly disease. This approach has shown promise in treating liver cancer, where surgery is often not an option and available drugs are only moderately effective.
A study published in The Lancet Diabetes & Endocrinology found that diabetes and high BMI were responsible for 544,300 new cancer cases globally in 2012. The authors project a significant increase in the proportion of cancers attributable to these risk factors, particularly in low- and middle-income countries.
A study of over 200 studies found that moderate coffee drinking is associated with lower risks of death, heart disease, and certain cancers. However, high consumption during pregnancy or in women at risk of fracture may be detrimental. The authors suggest further randomized trials to confirm the findings.
Researchers discovered a synthetic double-stranded RNA that boosts anti-tumor innate immune functions, potentially preventing liver cancer. The study found that administering the RNA at different stages suppressed tumor formation in mouse models.
Researchers at the University of California San Diego School of Medicine found that chronic liver inflammation suppresses immunosurveillance, allowing cancer cells to grow. Inhibiting PD-L1 restored immune function and cleared tumors in mice with NASH-associated mutations.
Research shows long-term aspirin use significantly reduces digestive cancer incidence, with substantial reductions in liver and oesophageal cancers. Aspirin use also shows promise in reducing risk of certain other cancers, while raising cardiovascular risk when stopped.
A study by researchers from Duke-NUS Medical School and Taiwan found that liver cancers exposed to Aristolochic Acids have AA-related mutations, with high prevalence in East and Southeast Asia. The findings highlight the need for public education and awareness about the dangers of AA in herbal products.
A USC research team has identified a potential therapeutic target for liver cancer treatment: mitophagy, the removal of damaged mitochondria. This process can cause tumors to proliferate, but temporarily halting it may reduce cancer stem cell growth, leading to tumor regression.
A study published in Gastroenterology identifies the gene mutation responsible for fibrolamellar hepatocellular carcinoma, a rare form of liver cancer mainly affecting children and young people. The researchers used CRISPR/Cas9 technology to introduce the mutation into mice, resulting in 12 out of 15 developing tumors.
A new study estimates that there were 854,000 new cases of liver cancer and 810,000 deaths worldwide in 2015. The majority of these cases were attributed to hepatitis B virus and alcohol consumption, highlighting the need for prevention and treatment strategies.
Researchers found two types of T cells respond differently to cancer antigens, with one starting strong but exhausting quickly and the other staying on target for a longer antitumor effect. The study suggests that targeting the persistent T cell type could lead to more effective cancer vaccines.
A recent study found that chronic cell death promotes the development of liver cancer by causing remaining cells to divide at higher rates. The researchers also identified caspase 8 as an enzyme playing a dual role in this process, involving both apoptosis and DNA repair.
Researchers discovered that caspase-8 triggers programmed cell death in diseased liver cells, leading to genetic instability and tumor development. This mechanism is remarkably universal across various liver diseases.
Researchers at KAIST have developed a novel method to improve medication treatment for liver cancer, identifying the resistance mechanism of Sorafenib and discovering a new approach to block it. The study suggests the possibility of developing a new method to overcome drug resistance using network analysis.
Researchers have developed a rapid portable test for liver cancer that can detect the disease in two minutes and can be administered wherever the patient is. The test uses gold nanoparticles to trap biomarkers from biological fluids, making it a potential game-changer in combating this deadly disease.
A little-studied gene SLC13A5 may explain how liver cancer cells obtain energy to proliferate. Suppressing SLC13A5 in human hepatocellular carcinoma cell lines resulted in slower growth and division of cancer cells.
Researchers at the University of Missouri found that women with increased cadmium levels have a higher risk of endometrial cancer, with rates increasing by 22% in individuals with elevated levels. The study recommends limiting cadmium intake through diet and lifestyle changes to reduce associated cancer risks.
Inlighta Biosciences is developing a novel, protein-based MRI contrast agent called ProCA32 to detect early stages of liver cancers and other metastatic tumors. The agent has shown improved imaging contrast compared to conventional agents, enabling earlier detection and characterization of cancerous lesions.
Researchers identified a key signaling pathway causing bile duct cancer and found possibilities to interrupt it. High ROS levels and TNF production promote tumor growth, but antioxidants and JNK inhibitors can stop tumorigenesis.
Exposure to particulate air pollution after liver cancer diagnosis significantly increases risk of premature death. Higher exposure levels further elevate the risk of dying from liver cancer or any cause.
In liver cancer, Scrib's increased expression suppresses the growth of cancer cells by inhibiting three oncogenes. The study provides the first hard evidence that Scrib functions as a tumor suppressor in human and animal liver cancer.
The CheckMate 040 study found that nivolumab produces durable responses with long-term survival rates of up to 59.9% in sorafenib-experienced patients with advanced HCC, regardless of Hepatitis B or C infection status.
Sub-Saharan African-born blacks experience a higher incidence of infection-related cancers and blood cancers compared to US-born non-Hispanic blacks. In contrast, prostate cancer is more prevalent among Western African-born black men, while Eastern African-born blacks have higher rates of liver and thyroid cancer.
Research identifies PPARγ as a critical regulator of metabolism-associated genes in the liver. Inhibition of PPARγ suppresses tumor growth and reduces tumorigenesis in mouse models.
Researchers developed a novel therapy using iPS-cell derived immune cells that produce interferon-β to combat liver cancer. The treatment was found to inhibit tumor cell proliferation and cause death, with high concentrations of IFN-β detected at targeted sites.
Researchers at MIT have developed a way to detect aflatoxin exposure by sequencing DNA of liver cells, potentially leading to earlier diagnosis and treatment. The technique can identify rare mutations caused by aflatoxin long before tumors form.
Sanford Simon at Rockefeller University has received a $600,000 grant from the Fibrolamellar Cancer Foundation to develop a therapy for fibrolamellar hepatocellular carcinoma. The disease typically affects adolescents and young adults with no history of liver disease, and there is currently no standard treatment regimen.
A new study published in Diabetologia found that having type 2 diabetes increases the risk of death from any form of cancer by 26%, even when controlling for other factors. The research also revealed statistically significant links between T2D and specific cancers, including liver, pancreas, breast, kidney, and endometrium.
A recent study discovered that liver cancer drugs fail because the body lacks a balance between two enzymes, Shp2 and Pten. This imbalance activates molecules involved in lipid metabolism, inflammation, and fibrosis, leading to liver disease and cancer.
A new study found that cancer cases are growing at an alarming rate in less developed countries, with a 50% increase between 2005 and 2015. The global burden of disease is heaviest for countries with high development levels, but the most rapid escalation can be seen in low-income nations where health services are often lacking.
Researchers have developed a new minimally invasive approach using gold nanoparticles encapsulated by gum Arabic to target and destroy precancerous tumor cells in the livers of mice. The study shows that this 'green' nanotechnology approach can suppress liver preneoplastic lesions with minimal damage to healthy tissue.
Researchers found that jet lag increases both obesity-related liver disease and liver cancer risk by disrupting the body's internal homeostasis. The study suggests that lifestyle changes leading to chronic jet lag can also increase liver cancer risk in humans.
A new study from UT Southwestern Medical Center found that proactive outreach to cirrhosis patients doubled their screening rates for liver cancer. The study successfully improved early detection and survival rates among those at highest risk of adverse outcomes. Only one-fourth of cirrhosis patients are currently screened every six mo...
New report predicts 7,100 cancer deaths annually by 2035 linked to alcohol, with oesophageal cancer seeing largest increase. The NHS will face a £2 billion treatment bill, while over 1.2 million hospital admissions are forecasted.
A study by the University of Leeds found that Reovirus, a common childhood cough virus, can stimulate the body's immune system to kill off liver cancer cells and the hepatitis C virus. The researchers hope to start clinical trials to test its effectiveness in treating primary liver cancer.
A large prospective cohort study found associations between high BMI, waist circumference, and type 2 diabetes with increased risk for liver cancer. The study, published in Cancer Research, adds substantial support to the link between obesity-related cancers, including liver cancer.
A new study by Thomas Jefferson University shows that community outreach workers may help increase hepatitis B vaccine uptake among Asian Americans, reducing the risk of liver cancer. The program involved lay health workers who provided personalized calls to encourage vaccinations.
Researchers at the University of Edinburgh have identified Notch 3 as a key driver of bile duct cancer. The molecule triggers a pathway that drives cells in tumours to reproduce uncontrollably, offering potential for new treatments.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that a key signaling protein helps suppress inflammation and scarring in the liver. The study suggests that p62, which is usually absent from cells that initiate inflammatory signals, plays a crucial role in preventing liver cancer progression.
Researchers from Charité have found that high blood selenium levels are associated with a decreased risk of developing liver cancer. Selenium deficiency is identified as a major risk factor for liver cancer, with the third of the population having lowest selenium status facing a five- to ten-fold increased risk.
Researchers developed an algorithm called JAMMIT that uses advanced mathematics to identify patterns across multiple molecular data types. The algorithm can accurately predict which patients would benefit most from chemotherapy and combining it with immunotherapy, leading to improved clinical outcomes and reduced costs.
Researchers found that low doses of paclitaxel, a widely used breast cancer treatment, can actually increase cancer spread to the liver. This contradicts previous strategies of lowering dosage to reduce toxic side effects.
Researchers block glutamine breakdown in liver cancer cells, preserving normal cells, and reduce tumor development in mice. The study identifies LRH-1 as the key protein involved and suggests it as a new target for treating liver cancer.
Researchers from Thomas Jefferson University have identified a panel of microRNAs in blood samples that can predict patients at high risk of developing hepatocellular carcinoma, the most common type of liver cancer, in individuals infected with hepatitis B virus.
A University of Colorado study found that Hispanic white and non-Hispanic black young adults are more likely to die from cancer than their white counterparts, with mortality risks ranging from 1.36 to 1.77 times higher.
Research found that high levels of the protein p62 are strongly associated with cancer recurrence and reduced patient survival in human liver samples. In mice, p62 was required for liver cancer to form. The study suggests p62 could be used as a prognostic marker and potential therapeutic target for liver cancer.
A recent study published in JAMA Internal Medicine found that higher levels of leisure-time physical activity were associated with lower risks for 13 types of cancers. The analysis included 1.4 million participants and 186,932 cancers identified during a median of 11 years of follow-up.
The Medical University of South Carolina's Hollings Cancer Center is awarded a grant to explore lipid signaling mechanisms in cancer cell proliferation, resistance to apoptosis, and metastasis. The project aims to develop new therapeutic strategies for solid tumors, including liver, prostate, and urinary cancers.
Dr. Hao Zhu has been awarded a $750,000 Stand Up To Cancer grant to investigate the relationship between injury, regeneration, and cancer. His research aims to understand the mechanisms shared by cancer and organ regeneration, with potential therapeutic targets in tissue repair and cancer prevention.
A study at the University of Texas M. D. Anderson Cancer Center found that normal liver cells metabolize dietary fructose differently than cancerous cells, revealing a potential diagnostic marker for liver cancer. The researchers discovered a gene called KHK that is expressed differently in healthy and tumor tissues.
A recent mouse study found that antioxidants in certain antidiabetic medications can accelerate the spread of colon and liver cancer. The findings suggest that these medications, which are commonly used to treat diabetes, may not be safe for diabetic patients with cancer.
CRI researchers found that inactivating a certain protein-coding gene promotes liver tissue regeneration in mammals. The study showed that mice without the gene had healthier livers, improved liver function, and faster healing of damaged tissues.
A new study suggests that consuming broccoli may protect against liver cancer and aid in countering the development of fatty liver disease. The researchers found that adding broccoli to a Westernized diet reduced the formation of cancer nodules in the liver and improved liver health.
Researchers at UT Southwestern Medical Center developed a nanoparticle therapy that combines LDL and fish oil to preferentially kill primary liver cancer cells. The approach shows significant anti-cancer activity, with over 80% of tumor cells dying, and holds promise for potentially treating other cancers.
A new report estimates 4.3 million new cancer cases and 2.8 million deaths in China in 2015, with lung cancer the leading cause of cancer death. The study highlights the need to reduce risk factors and improve clinical care delivery to prevent avoidable cancer deaths.
Researchers create synthetic nanoparticles that can deliver miRNA-based therapies to late-stage liver cancer, inhibiting tumor growth and extending survival. The breakthrough addresses a major challenge in treating aggressive liver cancer, offering hope for patients with limited treatment options.